Cargando…

Establishment and Validation of a Model for Disease-Free Survival Rate Prediction Using the Combination of microRNA-381 and Clinical Indicators in Patients with Breast Cancer

OBJECTIVE: We have found that miR-381 can regulate the proliferation of breast cancer cells by regulating TWIST protein, it can serve as a potential marker for the tumor progression. Thus, we herein establishment and validation of a model for predicting disease progression in patients with breast ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Jun, Wang, Meng, Li, Fan, Yan, Huanhuan, Wang, Rui, Zhou, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719690/
https://www.ncbi.nlm.nih.gov/pubmed/36475295
http://dx.doi.org/10.2147/BCTT.S383121
_version_ 1784843381499756544
author Shen, Jun
Wang, Meng
Li, Fan
Yan, Huanhuan
Wang, Rui
Zhou, Jun
author_facet Shen, Jun
Wang, Meng
Li, Fan
Yan, Huanhuan
Wang, Rui
Zhou, Jun
author_sort Shen, Jun
collection PubMed
description OBJECTIVE: We have found that miR-381 can regulate the proliferation of breast cancer cells by regulating TWIST protein, it can serve as a potential marker for the tumor progression. Thus, we herein establishment and validation of a model for predicting disease progression in patients with breast cancer using a combination of microRNA-381 (miR-381) and clinical indicators. METHODS: Data from 160 breast cancer patients in the First People’s Hospital of Lianyungang were collected, The relationship between miR-381 expression and tumor subtype was analyzed. The Kaplan–Meier (K–M) curve method was used to investigate the disease-free survival rate, while multivariate Cox regression analysis was used to investigate the risk factors affecting the prognosis of the patients. A model for predicting disease progression was subsequently established and validated. RESULTS: The miR-381 was significantly higher in the stage I patients than stage II/III patients. The miR-381 level of triple-negative breast cancer (TNBC) type was significantly decreased. The miR-381 could be used to effectively predict the prognosis, using cut-off value of 0.2515, with a sensitivity of 65.38% (51.8–76.85%), specificity of 75.00% (46.77–91.11%). The K–M survival curve indicated that the patients with higher miR-381 expression had a better prognosis. The miR-381+Ki-67+TN model and TN (T and N in TNM staging) model were established and subsequently compared. The TN model had an area under the curve (AUC) of 0.479 (95% CI 0.329, 0.629); in comparison, the our model had an AUC of 0.719 (95% CI 0.580, 0.857), showing better performance. CONCLUSION: The miR-381 expression was correlated with different (TNM) stages and tumor subtypes. The higher the TNM stage, the lower the miR-381 expression in the tumor tissue, while it was significantly decreased in TNBC. A prediction model consisting of combination of miR-381 and Ki-67 and TN indicators could predict disease progression more effectively.
format Online
Article
Text
id pubmed-9719690
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-97196902022-12-05 Establishment and Validation of a Model for Disease-Free Survival Rate Prediction Using the Combination of microRNA-381 and Clinical Indicators in Patients with Breast Cancer Shen, Jun Wang, Meng Li, Fan Yan, Huanhuan Wang, Rui Zhou, Jun Breast Cancer (Dove Med Press) Original Research OBJECTIVE: We have found that miR-381 can regulate the proliferation of breast cancer cells by regulating TWIST protein, it can serve as a potential marker for the tumor progression. Thus, we herein establishment and validation of a model for predicting disease progression in patients with breast cancer using a combination of microRNA-381 (miR-381) and clinical indicators. METHODS: Data from 160 breast cancer patients in the First People’s Hospital of Lianyungang were collected, The relationship between miR-381 expression and tumor subtype was analyzed. The Kaplan–Meier (K–M) curve method was used to investigate the disease-free survival rate, while multivariate Cox regression analysis was used to investigate the risk factors affecting the prognosis of the patients. A model for predicting disease progression was subsequently established and validated. RESULTS: The miR-381 was significantly higher in the stage I patients than stage II/III patients. The miR-381 level of triple-negative breast cancer (TNBC) type was significantly decreased. The miR-381 could be used to effectively predict the prognosis, using cut-off value of 0.2515, with a sensitivity of 65.38% (51.8–76.85%), specificity of 75.00% (46.77–91.11%). The K–M survival curve indicated that the patients with higher miR-381 expression had a better prognosis. The miR-381+Ki-67+TN model and TN (T and N in TNM staging) model were established and subsequently compared. The TN model had an area under the curve (AUC) of 0.479 (95% CI 0.329, 0.629); in comparison, the our model had an AUC of 0.719 (95% CI 0.580, 0.857), showing better performance. CONCLUSION: The miR-381 expression was correlated with different (TNM) stages and tumor subtypes. The higher the TNM stage, the lower the miR-381 expression in the tumor tissue, while it was significantly decreased in TNBC. A prediction model consisting of combination of miR-381 and Ki-67 and TN indicators could predict disease progression more effectively. Dove 2022-11-30 /pmc/articles/PMC9719690/ /pubmed/36475295 http://dx.doi.org/10.2147/BCTT.S383121 Text en © 2022 Shen et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Shen, Jun
Wang, Meng
Li, Fan
Yan, Huanhuan
Wang, Rui
Zhou, Jun
Establishment and Validation of a Model for Disease-Free Survival Rate Prediction Using the Combination of microRNA-381 and Clinical Indicators in Patients with Breast Cancer
title Establishment and Validation of a Model for Disease-Free Survival Rate Prediction Using the Combination of microRNA-381 and Clinical Indicators in Patients with Breast Cancer
title_full Establishment and Validation of a Model for Disease-Free Survival Rate Prediction Using the Combination of microRNA-381 and Clinical Indicators in Patients with Breast Cancer
title_fullStr Establishment and Validation of a Model for Disease-Free Survival Rate Prediction Using the Combination of microRNA-381 and Clinical Indicators in Patients with Breast Cancer
title_full_unstemmed Establishment and Validation of a Model for Disease-Free Survival Rate Prediction Using the Combination of microRNA-381 and Clinical Indicators in Patients with Breast Cancer
title_short Establishment and Validation of a Model for Disease-Free Survival Rate Prediction Using the Combination of microRNA-381 and Clinical Indicators in Patients with Breast Cancer
title_sort establishment and validation of a model for disease-free survival rate prediction using the combination of microrna-381 and clinical indicators in patients with breast cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719690/
https://www.ncbi.nlm.nih.gov/pubmed/36475295
http://dx.doi.org/10.2147/BCTT.S383121
work_keys_str_mv AT shenjun establishmentandvalidationofamodelfordiseasefreesurvivalratepredictionusingthecombinationofmicrorna381andclinicalindicatorsinpatientswithbreastcancer
AT wangmeng establishmentandvalidationofamodelfordiseasefreesurvivalratepredictionusingthecombinationofmicrorna381andclinicalindicatorsinpatientswithbreastcancer
AT lifan establishmentandvalidationofamodelfordiseasefreesurvivalratepredictionusingthecombinationofmicrorna381andclinicalindicatorsinpatientswithbreastcancer
AT yanhuanhuan establishmentandvalidationofamodelfordiseasefreesurvivalratepredictionusingthecombinationofmicrorna381andclinicalindicatorsinpatientswithbreastcancer
AT wangrui establishmentandvalidationofamodelfordiseasefreesurvivalratepredictionusingthecombinationofmicrorna381andclinicalindicatorsinpatientswithbreastcancer
AT zhoujun establishmentandvalidationofamodelfordiseasefreesurvivalratepredictionusingthecombinationofmicrorna381andclinicalindicatorsinpatientswithbreastcancer